* Amicus Therapeutics Inc FOLD.OQ reported a quarterly
adjusted
loss of 5 cents per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of -15 cents. The mean expectation of
twelve analysts for the quarter was for a loss of 6 cents per
share. Wall Street expected results to range from -10 cents to 2
cents per share.
* Revenue rose 34% to $126.67 million from a year ago;
analysts
expected $121.24 million.
* Amicus Therapeutics Inc's reported EPS for the quarter was
a
loss of 5 cents.
* The company reported a quarterly loss of $15.7 million.
* Amicus Therapeutics Inc shares had risen by 0.8% this
quarter and lost 29.5% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 29%
in the last three months.
* In the last 30 days, one analyst negatively revised an
earnings
estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Amicus
Therapeutics Inc is $18.50
This summary was machine generated from LSEG data August 8 at
01:32 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.06 -0.05 Beat
Mar. 31 2024 -0.07 -0.16 Missed
Dec. 31 2023 -0.06 -0.11 Missed
Sep. 30 2023 -0.08 -0.07 Beat